Catapults Home About us How we work Impact National coordination News Events Resources Contact us Working with researchers Working with companies Our capabilities Our facilities Collaborations Braintree, UK COVID-19 CGT Catapult Braintree Manufacturing Innovation Centre Manufacturing GMP manufacturing Vaccines The CGT Catapult Braintree, due to become fully operational by December 2021, is being developed following a £100m commitment by the Government to support the national effort to manufacture millions of doses of COVID-19 vaccine become an innovation centre for cell and gene therapies supporting the growth of this expanding industry continue to promote innovation and develop technology transfer expertise for vaccines and large-scale cell and gene therapy manufacture COVID-19 vaccine response Responding to the coordinated national effort backed by the UK Government led by the appointed Vaccine Taskforce, we are establishing the CGT Catapult Manufacturing Innovation Centre as a flexible facility to support the national and international response to the COVID-19 pandemic. We are installing state-of-the-art equipment, including up to 1,000L bioreactors, and providing our expertise to prepare the facility in Braintree for manufacturing millions of doses of vaccine per month. The centre is scheduled to become fully operational by December 2021 when it is forecast that COVID-19 vaccine candidates will be approved for use. The centre complements the Vaccines Manufacturing and Innovation Centre (VMIC) currently being built in Oxfordshire. It is important to have multiple facilities to build the manufacturing resilience needed to ensure the UK has long-term capacity to meet future pandemics. Centre for innovation and technology transfer expertise We are engaging with the whole industry, CDMOs and developers to determine the best way of supporting continued growth of the UK cell and gene therapy industry moving forward. The CGT Catapult Manufacturing Innovation Centre will become a state-of-the-art facility, developing expertise and driving innovation into technology transfer for novel therapies and vaccines manufacturing at industrial scale. Large-scale gene therapy manufacturing systems will also be developed at the facility as we aim to fulfil the immediate and long-term needs of the UK cell and gene therapy industry. Share Sign Up Related news view 28 JULY 2020 Positioning statement: CGT Catapult Manufacturing Innovation Centre view 23 JULY 2020 Press Release: Over £100m cash boost to manufacture millions of doses of COVID-19 vaccine All News @CGTCatapult Senior Scientist Dr Lily Li will be discussing the at qPCR & Digital PCR Congress on Tuesday 07 Decemb… https://t.co/Vdj0wVtY6u — 13 hours 21 min ago Discover who we are Contact Join our mailing list -> Sign up About us Catapult model Our team Our operating subsidiaries Vacancies How we work Working with researchers Working with companies Our capabilities Our facilities Collaborations Impact Case studies Annual Reviews National coordination Clinical adoption Skills development News Events Past events Resources Preclinical database Clinical trials database Publications Manufacturing surveys Cell Confluency Tool Mailing list Catapult Cell and Gene Therapy We work with innovate UK Terms and Conditions Privacy Policy Accessibility Policy Cookie Policy Contact us Sitemap We use cookies on this site to enhance your user experience By clicking the Accept button, you agree to us doing so. More info OK, I agree No, thanks